S1606 SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS

Authors :: G. Schiller
Nizar J. Bahlis
M. Baljevic
R. Kotb
S. Shacham
K. Rodriguez-Lopez
D. White
Jean-Richard Saint-Martin
H. Sheehan
H. Sutherland
J. Shah
B. Lipe
W. Bensinger
C. Gasparetto
Christine Chen
M. Kauffman
M. Sebag
S. Lentzsch
C. Venne
N. Callander
R. LeBlanc
S. Tuchman
Source :: HemaSphere. 3:740
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Proteasome
business.industry
medicine
Daratumumab
In patient
Hematology
Pharmacology
business
medicine.disease
Dexamethasone
Multiple myeloma
medicine.drug

Full Text Access

Tools